Tessa shares optimized methods for RNA Virus (SIV) preservation from field-collected fecal and saliva samples at the Midwest Primate Interest Group Meeting in Ann Arbor, Michigan.

Vanessa shares results of a preliminary study evaluating the urine and stool microbiome (16S and shotgun metagenomics) and metabolomce (LC-MS) of dogs with and without bladder cancer at the Veterinary Cancer Society Meeting in Norfolk, VA.

Vanessa Hale and a  team of clinicians at Ohio State University – Dr. Brian Husbands (Oncology), Dr. Adam Rudinsky (Internal Medicine), Dr. Sheryl Justice; the University of Missouri – Dr. Lindsey Donnelly (Oncology), Dr. Laura Nafe  (Internal Medicine); and North Carolina State University – Dr. Michael Mastromauro (Oncology), Dr. Allison Kendall (Internal Medicine) received funding to launch a muti-center, blinded, placebo-controlled clinical trial that tests the addition of Escherichia coli Nissle 1917 (EcN), a well-established probiotic, to a standard-of-care chemotherapy for the treatment of muscle invasive bladder cancer in dogs. The gut microbiota impacts response to cancer therapy and studies in humans demonstrate that manipulating the microbiota through probiotic use can improve cancer outcomes. Our goal is to test this using EcN in canine bladder cancer.

Congratulations to the whole team!

For more information, click here.